Collegium Pharmaceutical, Inc. (FRA:354)
Germany · Delayed Price · Currency is EUR | Market Cap | 646.41M -31.6% |
| Revenue (ttm) | 707.42M +14.3% |
| Net Income | 41.94M +32.1% |
| EPS | 1.23 +32.7% |
| Shares Out | n/a |
| PE Ratio | 15.41 |
| Forward PE | 2.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 19.10 |
| Previous Close | 19.10 |
| Day's Range | 19.10 - 19.40 |
| 52-Week Range | 18.50 - 42.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco... [Read more]
Financial Performance
In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.
Financial numbers in USD Financial StatementsNews
Collegium Pharmaceutical Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A diversified biopharma company projects $840 million in 2026 revenue, driven by strong ADHD portfolio growth and stable pain management revenues. Recent acquisitions, disciplined capital allocation, and robust cash flow support ongoing expansion and shareholder returns.
Collegium Pharmaceutical Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has rapidly diversified from pain management into ADHD, with new acquisitions driving significant revenue growth and a robust, complementary product portfolio. Strong execution, disciplined capital allocation, and a durable pain franchise support a vision for further diversification and expansion into new therapeutic areas.
Leerink bullish on Collegium Pharmaceutical, initiates with an Outperform
As previously reported, Leerink analyst Daniel Clark initiated coverage of Collegium Pharmaceutical (COLL) with an Outperform rating and $45 price target The firm names the stock a Top Pick and…
Collegium Pharmaceutical initiated with an Outperform at Leerink
Leerink initiated coverage of Collegium Pharmaceutical (COLL) with an Outperform rating and $45 price target
Collegium Pharmaceutical assumed with a Buy at Truist
Truist assumed coverage of Collegium Pharmaceutical (COLL) with a Buy rating with a price target of $49, down from $58. Collegium offers an attractive setup as durable cash flow from…
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and...
Collegium Pharmaceutical price target lowered to $48 from $56 at Barclays
Barclays lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $48 from $56 and keeps an Overweight rating on the shares. The firm reduced estimates post the Q2 report…
Collegium Announces $50 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and ...
Collegium Pharmaceutical Earnings Call Transcript: Q2 2026
Q2 2026 saw strong ADHD portfolio growth, with JORNAY PM and AZSTARYS driving revenue gains and market share, while pain portfolio revenues were mixed due to pricing pressures. Full-year guidance was raised for AZSTARYS, and capital deployment remains disciplined.
Collegium Pharmaceutical Quarterly report: Q2 2026
Collegium Pharmaceutical has published its Q2 2026 quarterly earnings report on August 6, 2026.
Collegium Pharmaceutical Earnings release: Q2 2026
Collegium Pharmaceutical released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Collegium Pharmaceutical Slides: Q2 2026
Collegium Pharmaceutical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated ...
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
STOUGHTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and ...
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln
BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, h...
Collegium Pharmaceutical to relocate corporate headquarters to Boston
Collegium Pharmaceutical (COLL) announced plans to relocate its corporate headquarters to One Lincoln in downtown Boston in the first quarter of 2027.
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
STOUGHTON, Mass., July 20, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) a leading biopharmaceutical company focused on improving the lives of people living with serious and o...
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STOUGHTON, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it awarded inducement grants on June 1, 2026 under the Company's 2026 Inducement Plan ...
Collegium Pharmaceutical Transcript: Jefferies Global Healthcare Conference 2026
The company projects robust growth in both pain management and ADHD, with durable revenues expected from its pain portfolio and significant expansion in ADHD following the AZSTARYS acquisition. Sales force integration and capital allocation remain focused on growth, debt reduction, and opportunistic share repurchases.
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global He...
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –
Collegium Pharmaceutical reports Q1 EPS $1.76, consensus $1.52
Reports Q1 revenue $193.52M, consensus $184.46M. “In the first quarter, we made meaningful progress on our 2026 strategic priorities, including delivering strong performance for JORNAY PM and continue...
Collegium Pharmaceutical backs FY26 revenue view $805M-$825M, consensus $839.15M
Backs FY26 adjusted EBITDA view $455M-$475M.
Collegium Pharmaceutical Earnings Call Transcript: Q1 2026
Q1 2026 saw 9% revenue growth, strong cash flow, and robust ADHD and pain portfolio performance. The $650M AZSTARYS acquisition is set to boost ADHD offerings and extend revenue into the late 2030s, with immediate EBITDA accretion expected.
Collegium Pharmaceutical Earnings release: Q1 2026
Collegium Pharmaceutical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.